Abstract
Farmatsevtika xizmatlari bozori sog‘liqni saqlash tizimining strategik sektori bo‘lib, dori vositalarining xavfsizligi, iqtisodiy mavjudligi va narx barqarorligini ta’minlashda davlat tomonidan samarali tartibga solishni talab etadi. O‘zbekiston sharoitida dori narxlarining beqarorligi, importga yuqori qaramlik hamda kompensatsiya mexanizmlarining cheklanganligi farmatsevtika bozorida institutsional takomillashtirish zaruratini yuzaga keltirmoqda. Mazkur tadqiqot aralash metodologiya (mixed-method approach) asosida amalga oshirildi. Sifat tahlili orqali normativ-huquqiy va institutsional mexanizmlar o‘rganildi, miqdoriy tahlil doirasida esa 2020–2025 yillar kesimida CPI–medicine ko‘rsatkichlari asosida dori narxlarining dinamikasi baholandi. Dori vositalari WHO tasnifi asosida essential, ijtimoiy ahamiyatga ega, generik va innovatsion guruhlarga ajratilib, narx regulyatsiyasi instrumentlari benchmarking usulida Finlandiya tajribasi bilan qiyoslandi.
Keywords
Farmatsevtika xizmatlari bozoridori vositalari narx siyosatiReferens narxlash (reference pricing)Reimbursement tizimidori vositalarining xavfsizligigenerik substitutsiyaCPI–medicine indeksiinstitutsional regulyatsiya Farmatsevtika xizmatlari bozori sog‘liqni saqlash tizimining strategik sektori bo‘lib, dori vositalarining sifati, xavfsizligi va iqtisodiy mavjudligini ta’minlashda muhim rol o‘ynaydi. Ushbu bozor axborot nomutanosibligi va yuqori xavfsizlik risklari bilan tavsiflanadi, shu sababli davlat tomonidan litsenziyalash, sertifikatlash, farmakovigilans va narxlarni tartibga solish kabi mexanizmlar orqali nazorat qilinadi.
Biroq regulyatsiyaning yetarli emasligi kabi uning ortiqcha murakkablashuvi ham bozor samaradorligiga salbiy ta’sir ko‘rsatishi mumkin. Haddan tashqari normativ talablar bozorga kirish xarajatlarini oshirishi va dori narxlarining sun’iy o‘sishiga olib kelishi ehtimoli mavjud. Shu bois farmatsevtika sohasida xavfsizlik va iqtisodiy samaradorlik o‘rtasidagi muvozanatni ta’minlovchi optimal regulyatsiya modeli dolzarb ilmiy muammo hisoblanadi.
References
1. Kela (2024) Medicine expenses and reimbursements. Available at: https://www.kela.fi/medicine-expenses (Accessed: 23 February 2026)., 2. Martikainen, J.E. and Vogler, S. (2015) ‘Pharmaceutical pricing and reimbursement information in Finland’, Journal of Pharmaceutical Policy and Practice, 8(1), pp. 1–12., 3. Roos, J. (2019) Effect of reference pricing reform on Finnish pharmaceutical market. Master’s thesis. Aalto University., 4. Statistics Agency of the Republic of Uzbekistan (2024) Consumer Price Index (CPI) – medicines (2020–2024). Available at: https://stat.uz (Accessed: 23 February 2026)., 5. Usmanova, S. (2022) ‘State regulation of pharmaceutical activities of the Republic of Uzbekistan’, [Journal name if available], pp. 1–10., 6. Vogler, S. (2017) Pricing and reimbursement policies: impacts on access to medicines. Copenhagen: WHO Regional Office for Europe., 7. WHO and World Bank (2023) Tracking universal health coverage: 2023 global monitoring report. Geneva: World Health Organization. Available at: https://www.who.int/publications/i/item/9789240080379 (Accessed: 23 February 2026)., 8. Pharmaceuticals Pricing Board (HILA) (2024) Reference price system and pricing decisions. Available at: https://hila.fi/en/ (Accessed: 23 February 2026).
